Published 2021
| Version v1
Publication
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
- Creators
- Clavio M.
- Crisa E.
- Miglino M.
- Guolo F.
- Ceccarelli M.
- Salvi F.
- Allione B.
- Ferrero D.
- Balleari E.
- Finelli C.
- Poloni A.
- Selleri C.
- Danise P.
- Cilloni D.
- Di Tucci A. A.
- Cametti G.
- Freilone R.
- Fanin R.
- Bigazzi C.
- Zambello R.
- Crugnola M.
- Oliva E. N.
- Centurioni R.
- Alesiani F.
- Catarini M.
- Castelli A.
- Abbadessa A.
- Capalbo S. F.
- Musto P.
- Angelucci E.
- Santini V.
- Others:
- Clavio, M.
- Crisa, E.
- Miglino, M.
- Guolo, F.
- Ceccarelli, M.
- Salvi, F.
- Allione, B.
- Ferrero, D.
- Balleari, E.
- Finelli, C.
- Poloni, A.
- Selleri, C.
- Danise, P.
- Cilloni, D.
- Di Tucci, A. A.
- Cametti, G.
- Freilone, R.
- Fanin, R.
- Bigazzi, C.
- Zambello, R.
- Crugnola, M.
- Oliva, E. N.
- Centurioni, R.
- Alesiani, F.
- Catarini, M.
- Castelli, A.
- Abbadessa, A.
- Capalbo, S. F.
- Musto, P.
- Angelucci, E.
- Santini, V.
Description
Azacitidine (AZA) is the standard treatment for myelodysplastic syndromes (MDS); however, many patients prematurely stop therapy and have a dismal outcome.
Additional details
- URL
- http://hdl.handle.net/11567/1096497
- URN
- urn:oai:iris.unige.it:11567/1096497
- Origin repository
- UNIGE